Nuvalent, Inc.

As of June 17, 2025, Nuvalent, Inc. shows a neutral technical stance with mixed signals, indicating a sideways trend despite some mildly bullish indicators on the weekly MACD and RSI.

Nuvalent, Inc. is a mid-cap pharmaceutical and biotechnology company with a market cap of approximately $5.46 billion. As of March 2025, it reported a net profit loss of $85 million and has no dividend yield.

As of Jun 18, Nuvalent, Inc. has a market capitalization of 5,461.77 million, with total assets of 1,141.75 million and shareholder's funds of 1,069.79 million. The company reported net sales of 0.00 million and a net profit of -300.85 million over the latest four quarters.